GlassScriptPhysician profile
Vishnu N Behari
NPI 1447202874
$23,503.99
in general payments reported to CMS, 2019-2025
47 companies · $2,732 in 2025
The $2,732 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,413 · 2020: $2,624 · 2021: $3,676 · 2022: $2,935 · 2023: $2,141 · 2024: $2,982 · 2025: $2,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,833 · Travel and Lodging: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,833.44 |
| Travel and Lodging | $1,021.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,393.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $2,653.18 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Guardian Sensor (3) |
| Lilly USA, LLC | $2,573.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $2,445.32 | 2019-2024 | |
| Medtronic Minimed, INC. | $2,149.62 | 2019-2020 | |
| Amgen INC. | $1,690.99 | 2019-2025 | Tepezza, Repatha, Evenity |
| Corcept Therapeutics | $1,083.31 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $804.43 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $667.55 | 2019-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $647.09 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $534.65 | 2019-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $392.87 | 2019-2022 | |
| Abbvie INC. | $384.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $361.13 | 2019-2022 | |
| Horizon Therapeutics Plc | $354.57 | 2021-2023 | Tepezza |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $353.70 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Clarus Therapeutics INC. | $330.57 | 2021 | |
| Amarin Pharma, INC. | $316.73 | 2019-2022 | |
| Insulet Corporation | $265.04 | 2019-2023 | Omnipod |
| Radius Health, INC. | $256.25 | 2019-2022 | |
| Abbott Laboratories | $224.57 | 2019-2024 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $170.38 | 2023-2025 | Crysvita |
| Beta Bionics, INC. | $167.94 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $163.21 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Shire North American Group INC | $119.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $117.09 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $104.06 | 2025 | Strensiq |
| Eisai INC. | $94.15 | 2019 | |
| Recordati_rare_diseases_inc. | $87.93 | 2021-2025 | Isturisa |
| Nevro Corp. | $83.47 | 2022-2024 | Senza |
| Novartis Pharmaceuticals Corporation | $81.03 | 2021-2025 | |
| Becton, Dickinson and Company | $57.72 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $56.92 | 2021-2024 | Unithroid |
| Ibsa Pharma INC. | $44.69 | 2022-2024 | Licart, Tirosint |
| Tolmar, INC. | $39.22 | 2024 | |
| Currax Pharmaceuticals LLC | $30.26 | 2021-2024 | Contrave |
| Kvk-Tech, INC. | $28.65 | 2019-2022 | |
| Mannkind Corporation | $27.02 | 2019 | |
| Amryt Pharma Holdings LTD | $22.73 | 2021 | |
| Ascendis Pharma Endocrinology INC | $18.57 | 2025 | Yorvipath |
| Verity Pharmaceuticals INC. | $16.69 | 2024 | Tlando |
| Ipsen Biopharmaceuticals, INC | $16.67 | 2019 | |
| Zealand Pharma US, INC. | $16.02 | 2022 | |
| Halozyme INC | $15.02 | 2023 | |
| Vivus LLC | $15.00 | 2019 | |
| Eusa Pharma (US) LLC | $14.53 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishnu Behari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.